Best Foundayo (Orforglipron) Providers in 2026 — Ranked & Reviewed
Foundayo (orforglipron) is the first FDA-approved oral GLP-1 receptor agonist for chronic weight management, approved on April 1, 2026 by Eli Lilly. Commercial dispensing started on April 6, 2026 and the provider list is small but growing fast. We track every US telehealth platform and pharmacy confirmed as a Foundayo channel, with pricing tiers verified directly from each provider's website. The Lilly Savings Card brings the price to $25/month for commercially insured patients, $149-$299/month for cash-pay. We update this list weekly as more providers come online.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Quick Picks: Top 5
Detailed Reviews
Amazon One Medical
Best for: the most authoritative branded GLP-1 channel with same-day delivery and integrated manufacturer savings
Amazon One Medical is the unified Amazon GLP-1 channel — One Medical clinicians prescribe FDA-approved Wegovy, Zepbound, and Foundayo (no compounded products), and Amazon Pharmacy fulfills with same-day delivery across roughly 3,000 US cities plus pickup kiosks at select One Medical locations. No prior membership required; insurance and cash pay both accepted. Foundayo launched at $25/month with insurance and the Lilly Savings Card, or $149/month cash pay.
Score Breakdown
Pros
- ✓As low as $1/day ($25/month) for brand-name Foundayo with insurance and the auto-applied Lilly coupon
- ✓Same-day delivery in nearly 3,000 US cities at launch, expanding to 4,500 by end of 2026
- ✓In-office pharmacist kiosks at select One Medical clinics let you walk out with Foundayo in hand
- ✓Cash-pay $5/day ($149/month) is competitive for the same FDA-approved brand-name product
- ✓Real-time availability, transparent pricing, and automatic manufacturer coupon at checkout
- ✓Delivering GLP-1 medications since 2021 — track record on cold-chain logistics
Cons
- ✗Headline $25/month needs both insurance and the Lilly Savings Card — uninsured pay $149/month
- ✗Same-day delivery is geographically gated; outside major cities it drops to next-day or slower
- ✗Pricing is set by manufacturer savings programs and can change at any time
- ✗No compounded options — brand-name only (Foundayo, Wegovy, Zepbound)
- ✗Wegovy/Zepbound pricing isn't shown upfront — depends on insurance at the prescribing visit
- ✗Copays and deductibles still apply to the clinical visit
LillyDirect Foundayo
Best for: patients with commercial insurance who want the cheapest legal brand-name GLP-1
Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss. With the Lilly Savings Card, commercially insured patients pay $25/month; cash-pay patients pay $149-$299/month depending on labeled dose. Requires a valid US prescription from any licensed prescriber.
Score Breakdown
Pros
- ✓Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
- ✓Direct from manufacturer — no compounding, no third-party reseller
- ✓Daily oral pill, no injections, no refrigeration
- ✓Available in all 50 states
Cons
- ✗Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
- ✗Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
- ✗$25 savings card requires commercial insurance — Medicare and Medicaid not eligible
- ✗Strict empty-stomach 30-minute window may be hard for some patients to follow
GoodRx
Best for: self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies
GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. Offers self-pay discount pricing for brand-name GLP-1 medications — Foundayo (orforglipron) starting at $149/month and Zepbound KwikPen (tirzepatide) starting at $299/month — redeemable at 70,000+ pharmacies nationwide. Also operates GoodRx Care, a telehealth arm offering GLP-1 prescriptions with online visits starting at $39.
Score Breakdown
Pros
- ✓$149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- ✓$299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- ✓Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- ✓No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- ✓Brand-name FDA-approved medication, not compounded
- ✓Manufacturer-direct pricing — Lilly delivers the discount through GoodRx, not a third-party negotiation
- ✓GoodRx Care telehealth offers GLP-1 prescriptions ($39–$70 per visit, $19 with Gold) — one-stop for script plus card
Cons
- ✗Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- ✗Self-pay only — does not apply toward insurance benefits or deductibles
- ✗Headline price applies to the lowest Foundayo dose; higher doses may cost more
- ✗No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- ✗Pricing can change as Lilly's manufacturer coupon program evolves
WeightWatchers
Best for: Foundayo access with a structured behavior-change program
WeightWatchers offers Foundayo (orforglipron) through its Med+ program, with care delivered by the WeightWatchers Clinic affiliate medical group. Foundayo is self-pay at $149/mo for the starting dose and up to $299/mo at higher doses, billed separately from the Med+ membership ($25 first month, $74/mo after with a 12-month commitment). WW is one of the few non-pharmacy telehealth programs that lists Foundayo transparently.
Score Breakdown
Pros
- ✓One of the first non-pharmacy telehealth programs to list Foundayo transparently
- ✓Care delivered by WeightWatchers Clinic (affiliated medical group)
- ✓Supports all 6 Foundayo doses: 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, 17.2mg
- ✓Publishes self-pay drug price on the product page (rare for a telehealth program)
- ✓Combines pharmacotherapy with the WW Points/behavior-change program
Cons
- ✗Med+ membership ($25 first month, $74/mo ongoing) is billed separately from the drug cost — actual out-of-pocket is higher than the listed $149/mo
- ✗State availability list not published publicly — requires eligibility quiz
- ✗Insurance coverage for Foundayo not yet available per WW's own disclosure
- ✗No compounded GLP-1 option; Foundayo only
- ✗12-month Med+ commitment required to lock the introductory $25 price
Ro
Best for: broadest GLP-1 formulary including Foundayo on day-one of launch
Ro is one of the largest direct-to-patient telehealth companies in the US and operates the most comprehensive obesity care formulary in the category — compounded semaglutide, brand-name Wegovy and Zepbound, and as of April 9 2026, Eli Lilly's new oral GLP-1 Foundayo (orforglipron) starting at $149/month for the lowest dose plus membership.
Score Breakdown
Pros
- ✓One of the broadest GLP-1 menus: compounded semaglutide, brand Wegovy, brand Zepbound, and oral Foundayo (orforglipron)
- ✓Among the first telehealth platforms to offer oral Foundayo at launch (April 2026)
- ✓A licensed provider helps you pick the best GLP-1 based on cost, insurance, and your health goals
- ✓Nationwide delivery, including 99% of primary-care deserts
- ✓Both cash-pay and insurance-eligible options on one platform
Cons
- ✗Foundayo requires a recurring membership on top of the $149/mo drug price, so total cost runs higher
- ✗Foundayo pricing above the lowest dose isn't shown until intake
- ✗State availability and pharmacy partners aren't listed publicly — confirmed at signup
- ✗Membership and medication are billed separately, which can make the true monthly cost confusing
Kin Meds
Best for: compounded and brand-name GLP-1 plus a longevity stack on one platform
Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and pill, Zepbound and Foundayo from $149/mo. Beyond weight loss, it bundles a longevity and wellness menu — Sermorelin, NAD+, glutathione, TRT, plus hair, skin and sexual health — so members can manage multiple protocols on one account.
Score Breakdown
Pros
- ✓Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
- ✓Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
- ✓LegitScript verified
- ✓Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
- ✓Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health
- ✓Telehealth flow clearly disclosed: questionnaire, provider review, tailored plan, ongoing support
Cons
- ✗Legal entity name and state of incorporation not publicly disclosed
- ✗The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
- ✗Per-state availability not listed
- ✗$149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
- ✗Lab work and dose-titration support not clearly described
- ✗Breadth across 8+ categories signals a broad DTC platform, not a GLP-1 specialist
PrideRx
Best for: Brand-name-only GLP-1s (Zepbound, Wegovy Pill, Foundayo) fulfilled by LillyDirect and NovoCare
PrideRx is an LGBTQ+-friendly telehealth platform offering brand-name-only GLP-1 weight loss — Zepbound (tirzepatide) from $299/mo, Wegovy Pill (oral semaglutide) from $149/mo, and Foundayo (orforglipron) from $149/mo — fulfilled directly by LillyDirect and NovoCare. Membership is $25 the first month, then $99/mo, covering doctor visits and prescription management; medication is billed separately by the pharmacy. The platform also covers sexual health, PrEP, and hair loss.
Score Breakdown
Pros
- ✓All three brand-name GLP-1 options on one platform — Zepbound injection, Wegovy Pill, and Foundayo — no compounded substitutes
- ✓Medication ships from and is billed by LillyDirect or NovoCare; PrideRx never handles or re-sells the drug
- ✓Transparent published per-dose pricing with on-page verification dates
- ✓$99/mo membership includes doctor visits and prescription management; 24-hour prescription review
Cons
- ✗$99/mo membership on top of medication cost — all-in runs $248–$548/mo depending on drug and dose
- ✗Legal entity and prescribing medical group are not named on the site
- ✗No LegitScript certification visible
- ✗State availability is not published — telehealth consult rules vary by state
Related Rankings
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Orforglipron · Drugs and brands
- Foundayo · Drugs and brands
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- GLP-1 receptor · Mechanism
- STEP-1 · Major trials
- Compounded GLP-1 · Pharmacy and drug forms
Sources & methodology — as of June 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.